CCN2 and chronic kidney disease: These results demonstrate that the activation of the EGFR pathway by the new ligand CTGF regulates inflammatory processes (Figure 3) and identify EGFR as a potential therapeutic target for the treatment of chronic kidney disease and vascular diseases closely linked with kidney damage.